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The CLC-1 chloride channel, a member of the CLC-channel/transporter family, plays important roles for the physiological
functions of skeletal muscles. The opening of this chloride channel is voltage dependent and is also regulated by protons and
chloride ions. Mutations of the gene encoding CLC-1 result in a genetic disease, myotonia congenita, which can be inherited as an
autosmal dominant (Thomsen type) or an autosomal recessive (Becker type) pattern. These mutations are scattered throughout
the entire protein sequence, and no clear relationship exists between the inheritance pattern of the mutation and the location
of the mutation in the channel protein. The inheritance pattern of some but not all myotonia mutants can be explained by a
working hypothesis that these mutations may exert a “dominant negative” effect on the gating function of the channel. However,
other mutations may be due to different pathophysiological mechanisms, such as the defect of protein trafficking to membranes.
Thus, the underlying mechanisms of myotonia are likely to be quite diverse, and elucidating the pathophysiology of myotonia
mutations will require the understanding of multiple molecular/cellular mechanisms of CLC-1 channels in skeletal muscles,
including molecular operation, protein synthesis, and membrane trafficking mechanisms.
1. Introduction
Chloride (Cl−) channels are membrane proteins that consist
of Cl−-permeation pores. Different types of human cells
express Cl− channels in the cell membrane for various phys-
iological purposes. In the last several decades, ion channels
that conduct cations, such as sodium (Na+), potassium
(K+) or calcium (Ca2+) channels, have been studied more
extensively than anion channels. Nonetheless, Cl− chan-
nels are as abundant as cation channels, and they also par-
ticipate in many important physiological tasks, including the
maintainence of normal cellular excitability, the control of
neurotransmitter release, and the transport of ions across
epithelial cells, to name a few. The aim of this paper is to pro-
vide an up-to-date overview of the mechanism and the con-
sequence of the disruption of Cl− channel function. We will
focus on the physiology and pathophysiology of a Cl− chan-
nel critical for the function of skeletal muscles, the CLC-1
Cl− channel.
Cl− is the most abundant anion in most organisms. In
adult mammalian cells, the extracellular concentration of
Cl− is significantly higher than its intracellular counterpart,
resulting in a negative Cl− equilibrium potential (ECl) that is
exquisitely determined by an intracellular Cl− concentration.
Two secondary active transport systems contribute the most
to the regulation of the cytoplasmic Cl− level. The Na+-K+-
Cl− cotransporter (NKCC) normally accumulates Cl− in the
cell [1], whereas the K+-Cl− co-transporter (KCC) usually
transports Cl− out of the cell [2]. Most epithelial cells express
predominantly NKCC and display an ECl positive to the
resting potential [3, 4]. In contrast, the majority of mature
neurons have an enhanced expression of KCC, and there-
fore manifest a quite negative ECl—sometimes even more
negative than the resting potential [3, 5]. In skeletal muscle,
despite the presence of both NKCC and KCC, the contribu-
tion of secondary active transporters to ECl is rather small,
mainly due to the presence of an extraordinarily high Cl−
permeability that is virtually impossible to be counteracted
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by active transporters [6–9]. The ECl in skeletal muscle is
thusmainly set by passive electrochemical equilibrium of Cl−
according to the resting membrane potential which is pri-
marily determined by K+ equilibrium potential (EK). Recent
evidence, however, supports the idea that the secondary
active transporter NKCC may modulate the membrane
potential of skeletal muscle via its Cl− import function [10–
12]. Indeed, the muscle resting potential is never the same as
the value of EK while the ECl has been shown to be slightly
more positive than the resting membrane potential [13].
Furthermore, the value of the intracellular Cl− activity has
been shown to be slightly higher than would be expected for a
passive Cl− distribution [13]. These observations underscore
the contribution of the chloride conductance in determining
the resting membrane potential of skeletal muscles.
2. Physiological Roles of CLC-1 Channels in
Skeletal Muscles
Because of a large membrane Cl− conductance, up to 80%
of the resting sarcolemmal conductance [14–16], a relatively
negative ECl explains the physiological role of Cl
− channels
in the cell membrane of skeletal muscles (sarcolemma). For
example, activation of Cl− channels is essential for ensuring
the electrical stability of skeletal muscle by resetting its
membrane excitability to the resting state after firing an
action potential. Furthermore, a significant Cl− conductance
is also located in the transverse-tubule system [15, 17–19],
indicating that the presence of an effective Cl− homeostasis
system is crucial for the generation and propagation of action
potential in both the sarcolemmal and the transverse-tubule
system. Finally, emerging evidence suggests that disruptions
of the balance of ion channel functions in sarcolemma
may contribute to skeletal muscle fatigue [19–21]. During
intensive firing of muscle action potentials, K+ ions tend
to accumulate in the extracellular space up to 10mM
as the extracellular volume of skeletal muscles is limited.
The increase of extracellular K+ concentration results in
depolarization of membrane potential, and, consequently, a
partial inactivation of voltage-gated Na+ channels. If the Na+
channels that remain active fail to generate a sufficient Na+
inward current to overcome the shunting currents mediated
by the resting sarcolemmal Cl− conductance, the firing of
action potential is not possible, thereby leading to muscle
fatigue.
Although various types of Cl− channels are expressed
in skeletal muscles, the most abundant Cl− channel in
the sarcolemma is CLC-1 [4, 22], which is a member of
the CLC-channel/transporter family. The mammalian CLC
family consists of nine members: CLC-1, CLC-2, CLC-3,
CLC-4, CLC-5, CLC-6, CLC-7, CLC-Ka, and CLC-Kb [22–
24]. Among these members, CLC-1, CLC-2, CLC-Ka, and
CLC-Kb are Cl− channels, predominantly residing in the
plasma membrane. The rest of the CLC members (CLC-3
to CLC-7) are thought to be transporters, mostly located
in intracellular organelles. Like bacterial CLC proteins [25],
these mammalian CLC transporters are thought to mediate
the counter transport of H+ and Cl−; that is, they are Cl−/H+
antiporters [26, 27].
Among the four plasma membrane CLC-channels, CLC-
Ka and CLC-Kb channels are involved in transepithelial
transport in the kidney and the inner ear [4, 28]. CLC-2
channels can be activated by hyperpolarization, cell swelling,
and extracellular acidification [29, 30]. Northern analysis
indicates that brain, kidney, and intestine express relatively
high levels of CLC-2 channels, although these channel are
broadly expressed in various tissues as well [31]. In contrast,
CLC-1 channels are most abundantly expressed in the
skeletal muscle [32]. A very low level of CLC-1 expression,
however, has been reported in kidney, heart, smooth muscle,
and, more recently, glial cells [32, 33]. Since the CLC-
1 channel is the major sarcolemmal Cl− conductance,
mutations of the gene encoding this Cl− channel lead to
a significant muscle hyperexcitability in humans, mice, and
other animals [34–38], a situation known as “myotonia” [32,
39]. Myotonia is a muscle disease due to hyper-excitability of
skeletal muscles. Therefore, this disease can be caused either
by the gain of function of Na+ channels or a loss of function
of Cl− channels in the sarcolemma of skeletal muscles. In
the following sections we will focus on the defect of CLC-1,
starting with the CLC-1’s molecular properties.
3. Molecular Biophysics of CLC-1 Channels
CLC-1 is a voltage-gated channel, and the open probability
of CLC-1 channels increases with membrane depolarization.
The functional study of CLC-1 at the single-channel level
is challenging due to the small single-channel conductance
of this channel. Therefore, many functional properties of
CLC-1 are inferred from those found in its fish homologue,
the Torpedo CLC-0 Cl− channel [23]. One unique functional
feature in CLC-channels is that the channel opens to two
current levels separated by equidistance in the single-channel
recording trace (Figure 1). This feature has been identified
as the consequence of a “double-barreled” channel opening,
first found in CLC-0 in early 1980s [40, 41]. Later single-
channel recordings confirmed that the opening of CLC-1
channels also fluctuates between three different conductance
levels (Figure 1(a)), corresponding to the three functional
states: two pores closed; one open and one closed; and,
finally, both pores open [42]. These functional recordings
of CLC-0 and CLC-1 channels foretold the recent structural
findings from bacterial CLC proteins in which two identical
Cl−-transport pathways were found in one CLC functional
unit [43, 44].
The opening and closure of the two pores in CLC-0
and CLC-1 channels are controlled by two distinct gating
mechanisms [23]. One of these gating mechanisms controls
the opening and closure of two pores simultaneously, and
is therefore called “common gate”. In addition, each pore is
also controlled by a “fast gate” that operates independently
from the partner fast-gate. Thus, the activation of the Cl−
conducting pathway of CLC-1 channels requires the opening
of both the common gate and the fast gate. The open-
close transition of the fast gate operates at a time scale of
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Figure 1: Molecular functions of CLC-channels. (a) Single-channel recordings of CLC-1 showing the “double-barreled” behavior. Dotted
lines depict the three current levels: C: closed state, O1: one protopore open, and O2: both protopores open. Horizontal and vertical scale
bars represent 200ms and 0.2 pA, respectively. Notice that the three current levels are separated in equi-distance. Figure, taken from Saviane
et al. [42] (© Rockefeller University Press, 1999). (b) Effects of extracellular Cl− on the fast-gate open probability of the Torpedo CLC-0
Cl− channel. Left panel shows single-channel recordings of CLC-0 at different extracellular Cl− concentrations indicated on the left. The
calculated open probabilities of the fast gate in each Cl− concentration are shown on the right. Membrane potentials in all recordings are
−60mV. Right panel shows a summarized result for the Cl− effect on the fast-gate Po-V curve. The extracellular Cl− concentrations are
300mM and those indicated in the left panel. As the extracellular Cl− concentration is reduced (from 300mM to 1mM), the fast-gate Po-V
curve is shifted to the more depolarized membrane potential. A similar Cl− effect on the fast-gate Po-V curve has been observed in CLC-1.
Figures, taken from Chen and Miller [45] (© Rockefeller University Press, 1996).
milliseconds at negative membrane potentials. At the peak
of the action potential, the opening kinetics of CLC-1 can
be in the submillisecond range. Thus, the opening of CLC-
1’s fast-gate can counteract the depolarization generated by
the opening of Na+ channels during an action potential. This
gating mechanism is thus important for CLC-1 channels to
control the action potential in skeletal muscles. Mutations
that reverse the voltage dependence of CLC-1 channels
result in certain forms of myotonia (see below) because
these mutant channels are unable to open after membrane
depolarization. In addition to the control by membrane
potentials, the fast-gating is also regulated by Cl− and H+
[46, 47]. The regulation of CLC-1 and CLC-0 channels by
Cl− and H+ is thought to bear an evolutional relationship
to the Cl−/H+ counter transport function of their CLC
transporter counterparts [48], although the exact link
between the channel-gating mechanism and the Cl−/H+-
antiporter mechanism is not known. Interestingly, a recent
crystallographic study of a prokaryotic CLC protein provided
a potential mechanism for the exchange stoichiometry of
2 Cl− for 1 H+ [49]. The voltage dependence of the
fast gating is similar to that found in voltage-gated cation
channels; namely, the open probability (Po) is higher at
more depolarized membrane potentials [40, 41, 45, 50, 51].
However, unlike voltage-gated cation channels with the “S4”
transmembrane segment serving as the “voltage sensor” [52],
there is no such structure in CLC-0 and CLC-1 channels.
The voltage-dependent activation of the fast gate of CLC-
0 and CLC-1 is likely to arise from the coupling of Cl−
transport with the gating process [45, 46, 53]. This gating-
permeation couplingmechanismwas first proposed by Pusch
and his colleague [53], who demonstrated that the Po-V
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Figure 2: Molecular architecture of mammalian CLC molecules. (a) The composite structure of a generic CLC molecule consists of two
parts: the membrane region, represented by the crystal structure of E. coli CLC molecule (CLC-ec1) (top), and the cytoplasmic domain
represented by the crystal structure of the cytoplasmic domain of CLC-5. The two subunits are colored in green and blue, respectively. The
two curve lines in the membrane portion roughly depict the transport pathways of Cl− ions (purple spheres). Red residues are Glu 148 of
CLC-ec1, which correspond to Glu 232 of CLC-1. The negatively charged side chain of this residue obstructs the ion-transport pathway, and
therefore is hypothesized to be the fast gate of CLC-channels. The two space-filled molecules in orange color in the cytoplasmic domains
(one in each subunit) are ATP molecules seen in the crystal structure of the CLC-5’s cytoplasmic domain. Binding of ATP to CLC-1 inhibits
the common gating of CLC-1. (b) X-ray crystal structure of CmCLC, a CLC protein from a thermophilic red alga Cyanidioschyzon merolae.
Orange arrows point to the ATP-binding sites.
curve of the fast gating of CLC-0 channels was shifted toward
a more depolarized membrane potential by reducing the
extracellular Cl− concentration. At a constant voltage, there-
fore, reducing the extracellular Cl− concentration inhibits
the opening of the fast gate. More detailed experiments at
the single-channel level (Figure 1(b)) further showed that
extracellular Cl− increases the open probability of the fast-
gate by increasing the opening rate of the fast gate [45].
Later experiments also revealed the same dependent fast
gating mechanism for CLC-1 channels [46]. To explain this
gating effect, investigators have proposed a model in which
the binding of Cl− to the channel pore opens the fast gate
and the movement of Cl− across membrane electric field
constitutes the fundamental mechanism for the observed
voltage dependence [23]. This hypothesis was formulated
before the crystal structure of CLC molecules became
available. Later structural information from crystallographic
studies of bacterial CLC proteins revealed that the transport
pathway of CLC molecules appear to be obstructed by the
negatively charged side chain of a glutamate residue, and
Cl− in the pore may compete with this glutamate side chain
[43, 44].
4. Structural/Functional Relationship of
CLC-1 Channels
The gene of the human CLC-1 channel encodes a transmem-
brane protein consisting of 991 amino acids (AA). The
protein can be roughly divided into two parts, the amino
(N)-terminal transmembrane portion (up to∼ 590AA.) and
the carboxyl (C)-terminal cytoplasmic portion (Figure 2).
Although the molecular structure of CLC-1 has not
been solved, recent breakthroughs in obtaining the crystal
structure of bacteria CLC proteins [43, 44] and the crystal
structures of the C-terminal cytoplasmic domain of several
vertebrate CLC molecules, such as CLC-0 [54], CLC-5
[55] and CLC-K [56], have provided insightful structural
information for other homologous CLCmolecules. The CLC
protein from E. coli (CLC-ec1) consists of only ∼460 AA,
which form a structure corresponding to the N-terminal
transmembrane portion of CLC-1 [44] (Figure 2(a), upper
panel). This part of the channel protein is composed of
eighteen α-helices (helices 1 to 18, or helices A to R),
seventeen of which being membrane associated (helix A
is not inserted into the membrane). Most of these helices
are not perpendicular to the membrane, but severely tilted.
Moreover, many of these helices do not span the entire width
of the lipid membrane (Figure 2(a), upper panel). The most
interesting feature of the transmembrane portion of CLC
molecules is that a glutamate residue located at the beginning
of helix N (helix 14) protrudes its negatively charged side
chain into the Cl−-permeation pathway (Figure 2(a), red
residues in the upper panel). With the glutamate side chain
blocking the Cl−-permeation pore, Cl− permeation is not
possible [44]. Mutation of this glutamate residue to a neutral
amino acid in CLC-channels results in channels that appear
to have a fully open pore. The side chain of this glutamate
residue is therefore thought to be the gate that controls each
individual protopore. It is also thought that the competition
of Cl− with this glutamate side-chain may underlie the
aforementioned gating permeation mechanism thoroughly
characterized for CLC-0 and CLC-1 channels [23, 57–59].
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The C-terminal half of CLC-1 (from ∼AA 591 to the C-
terminus) is believed to be entirely located in the cytoplasmic
side of the membrane (Figure 2(a), lower panel). This
structure of the C-terminal cytoplasmic domain was initially
solved in several mammalian CLC molecules independent of
the transmembrane domain. A most recent crystallographic
study revealed the structure of CmCLC, a CLC protein from
thermophilic alga that consists of a transmembrane region
and a C-terminal cytoplasmic domain [49]. The transmem-
brane and cytoplasmic domains of the CmCLC structure are
similar to those solved previously in other CLC proteins,
including the extensive helical architecture in the transmem-
brane region and the characteristic cystathionine β-synthase
(CBS) domains in the cytoplasmic region (Figure 2(b)).
Thus, it is very likely that the C-terminal cytoplasmic domain
of CLC-1, like those in other mammalian CLC molecules,
also contains two tandem CBS domains that are folded
into a potential ATP-binding site. It has been shown that
cytoplasmic ATP can inhibit the current of CLC-1 channels
in acidic pH conditions [60–62], and the crystal structure of
the C-terminal region of the CLC-5 protein revealed an ATP
molecule bound to the predicted ATP-binding site formed
by the two tandem CBS domains [55] (Figure 2(a), lower
panel). The inhibition of CLC-1 channels by ATP is therefore
thought to be due to a direct ATP binding to the C-terminus
of protonated CLC-1 channels. Experimental evidence shows
that the effect of intracellular ATP is to make the opening
of the common gate more difficult [61]. The mechanism of
common gating of CLC-channels is not clear, but it has been
proposed that this gating mechanismmay involve the relative
motion of the two channel subunits, including themovement
of the C-terminal cytoplasmic domain [63]. The inhibition
of the common gating by cytoplasmic ATP is consistent with
the structural feature that the ATP-binding site is located in
the C-terminal cytoplasmic region of CLC-1 channels.
During vigorous muscle activities, ATP level in fast-
twitch muscle fibers is significantly lowered [64], which
in turn reduces ATP inhibition of CLC-1 channels. This
enhanced activation of CLC-1 channels is expected to
decrease muscle excitability, a potential cell protection
mechanism during metabolic stress that may contribute to
the development of muscle fatigue [65]. As discussed above,
muscle fatigue may also be caused by partial Na+ channel
inactivation as a result of the accumulation of extracellular
k+ ions after multiple action potentials. Moreover, intensive
exercise leads to muscle acidosis [66, 67], which in the
presence of ATP, may result in CLC-1 channel inhibition
[60]. This down regulation of membrane Cl− conductance
will notably reduce the input conductance of sarcolemma
and consequently increase the likelihood of spike induction
for the Na+ channels that remain active, and may therefore
serve as a physiological response to prevent the development
of muscle fatigue.
5. Pathophysiology of Myotonia Congenita
In humans, mutations in the skeletal muscle CLC-1 gene
(CLCN1) on chromosome 7 have been linked to a hereditary
muscle disease, myotonia congenita [68]. Myotonia can
be defined as a hyperexcitability of the plasma membrane
of skeletal muscle fibers. Myotonia is due to an electrical
instability of the muscle membrane itself, leading to repet-
itive action potentials with a single stimulus (“myotonic
runs”). Myotonia congenita was one of the first human
diseases proven to be caused by an ion-channel defect
(channelopathy). This discovery was based on studies in
goats with hereditary myotonia that closely resembled
myotonia congenita in humans [69–71]. Subsequent studies
also demonstrated that there was indeed a reduced Cl−
conductance in goat and human myotonic muscle fibers and
that normal muscle fibers exhibited myotonic features when
Cl− was replaced with an impermeant anion [14, 72]. This
myotonia-like phenomenon induced by low concentrations
of Cl− can be accounted for by the aforementioned Cl−-
dependent gating mechanism for CLC-1 channels.
Human myotonia congenita can be inherited in an
autosomal recessive (Becker type) or autosomal dominant
(Thomsen type) manner [73]. By now, more than 100
different mutations in the CLCN1 gene have been identified
in patients with myotonia congenita [74–76]. Myotonia-
causing mutations are scattered over the entire sequence
of the channel protein, both in the transmembrane region
and in the cytosolic N-terminal and C-terminal parts. They
include nonsense, splice-site, and frameshift mutations that
truncate the channel protein. Truncation mutations are
always associated with recessive myotonia, except when they
are very close to the C-terminus. Missense mutations can
be associated with either recessive or dominant inheritance.
Mutations with dominant inheritance are less frequent.
With the exception of truncations very close to the C-
terminus of CLC-1 channels, all dominant mutations are
missense mutations. Recessive mutations are more diverse;
they can be associated with truncations, insertions, splice
defects, missense, or nonsense/stop errors. Therefore, it is not
possible to predict on the basis of the mutation location or
the mutation type whether the inheritance will be dominant
or recessive.
For the autosomal dominant form of myotonia, patients
are expected to carry the heterozygous CLCN1 genotype: one
copy each of the wild-type and the mutant allele. Regarding
the molecular mechanism of myotonia congenita, a loss-of-
function phenotype of the mutant CLCN1 gene certainly
supports haploinsufficiency as a reasonable mechanism
causing the malfunction of muscles. For many other cases of
disease-related mutations, however, a total loss of functional
CLC-1 channels on only one allele does not lead to myotonia
[32, 36]. It has been suggested that dominant myotonia
is due to dominant-negative effects of the mutant subunit
on the wild-type subunit coexpressed in the muscles of
heterozygous patients. On the other hand, lots of CLCN1
gene mutations result in recessive myotonia, and the mutant
proteins do not have dominant negative effects. A likely
reason for a lack of dominant negative effects for these
recessive mutants is the inability of truncated proteins to
associate with the wild-type subunit [74].
Therefore, a current working hypothesis on the molec-
ular basis for the inheritance of myotonia congenita is that
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the inheritance pattern of a mutation is predominantly
determined by the functional consequence of the mutation
on the gating of CLC-1 channels: those mutations that
affect the common gate lead to an autosomal-dominant
inheritance pattern, whereas those affecting individual pro-
topores only result in a recessive pattern [42, 77]. As
described above, a functional CLC-1 channel is a homo-
dimer. With the exception of truncations very close to the
C-terminus of CLC-1 channels, all dominant mutations
are missense mutations. Almost all these mutations shift
the voltage-dependence of gating of the channel towards
positive voltages so that the activity of the mutant channels
is insufficient to cause membrane repolarization [53]. The
dominant-negative effect of these mutations on the hetero-
dimeric channel is due to the fact that the common-gate
controlling both protopores is affected by themutation in the
mutant subunit [42]. Indeed, many, but not all, mutations
in dominant myotonia are due to mutations of residues
close to the subunit interface [74, 75, 78]. Consistent with
this observation, site-directed mutagenesis of residues lining
subunit interface affects the common gate of CLC-1 [79, 80].
On the other hand, as the ion-conducting pore of CLC-
1 is entirely contained within each subunit of the dimer
[43, 81], mutations affecting the function of one proto-
pore are unlikely to affect the conductance of the second
subunit in wild-type/mutant hetero dimeric channels and
therefore will generally lack dominantnegative effects. For
example, the equivalent residue of CLC-1’s M485 in bacterial
CLC proteins is located in the ion-transport pathway. In
heterologous expression systems, the mutation M485V in
CLC-1 drastically changed the single-channel conductance
and the voltage-dependent gating of homodimeric mutant
CLC-1 channels [82]. This mutation, however, displays a
recessive inheritance pattern. As both alleles are mutated
in patients with recessive myotonia, a total loss of CLC-1
channel function may ensue. In contrast, by assuming equal
association affinity for both wild-type and mutant subunits
in the dimeric channel architecture, at least 25% of wild-type
currents will still remain in heterozygous patients carrying
dominant-negative mutations. Accordingly, recessive myoto-
nia is clinically more severe than the dominant Thomsen
form.
In addition to faulty channel gating, other mechanisms
may also contribute to the pathophysiology of myotonia
congenita [83]. For example, several recessive CLCN1 muta-
tions (e.g., Y150C, V165G, F167L, V236L, Y261C, V327I, and
F413C) have been shown to yield functional CLC-1 channels
with biophysical properties either only slightly different or
virtually indistinguishable from those of wild-type channels
[75]. Similarly, some dominant CLCN1 mutations (e.g.,
R338Q, F428S, and T550M) have been shown to display no
detectable gating defects upon forming heterodimers with
their wild-type counterparts [84, 85]. By no means can the
foregoing dominant negative mechanism explain the inher-
itance patterns of these mutations. These examples clearly
demonstrate that the effect of myotonia-related mutations
cannot be simply attributed to the disruption of the gating
of CLC-1 channels. Several novel mutations in the CLCN1
gene have recently been identified in Taiwanese patients
suffering from myotonia congenita [86, 87]. Interestingly,
one of the detected mutations, fs793X, was found in a
Taiwanese family with dominant inheritance pattern [87].
However, the same mutation was previously found in an
recessive Italian pedigree [88]. This is only one of the several
examples showing that the same mutations are associated
with recessive myotonia in some families, but with dominant
myotonia in others [77, 89, 90]. This dual inheritance pattern
again demonstrates the inadequacy of the gating hypothesis
and further highlights the importance of other pathophysi-
ological mechanisms of myotonia congenita. It is likely that
some myotonia congenita-related mutations may (i) result
in aberrant biogenesis and subunit assembly and/or (ii) lead
to a defective membrane targeting subcellular localization
patterns of CLC-1 channels. Indeed, three myotonia-related
mutations in the distal C-terminus of CLC-1 channels have
been shown to have a reduction of protein expression in the
surfacemembrane [83]. Thus, the underlyingmechanisms of
myotonia due to CLC-1 channelopathy are likely to be quite
diverse.
6. Clinical Correlation
Myotonia is characterized by the impaired relaxation of
skeletal muscle following sudden voluntary contraction. As
discussed above, CLC-1 conductance contributes up to 80%
of the resting membrane conductance in normal skeletal
muscle. Myotonia-causing mutations in the CLCN1 gene
therefore lead to a significant reduction in resting membrane
conductance, thereby increasing the input resistance of
skeletal muscle [72, 91]. Consequently, a smaller membrane
depolarization (threshold potential) will be sufficient to
trigger an action potential, that is, muscle excitability will be
enhanced. This scenario explains why a single nerve stimulus
elicited a train of action potentials in muscle fibers from
myotonic goats; in contrast, the same stimulus only induced
a single action potential in normal muscle fibers [70].
Another important role of CLC-1 conductance in muscle
is to counteract the depolarizing effect of tubular K+ accu-
mulation during intensive firing of action potentials [70].
As the extracellular volume in the transverse-tubule system
of skeletal muscles is limited, K+ ions tend to accumulate
in the extracellular space during intensive firing of muscle
action potentials. This increase in extracellular K+ normally
has little effect on the membrane potential due to the
presence of high CLC-1 conductance. In myotonic muscle,
however, a small accumulation of tubular K+ will result
in a significant membrane depolarization. In the presence
of rapid successions of action potentials, summation of
these K+ accumulation-induced membrane depolarization
may trigger spontaneous muscle action potentials, thereby
manifesting myotonia symptoms such as muscle stiffness
after voluntary contraction. Hence, the medication of choice
for myotonic patients usually involves drugs that suppress
muscle excitability via inhibition of voltage-gated Na+ chan-
nels [92].
The muscle stiffness of myotonia can gradually be re-
lieved by exercise (the so-called “warm-up” phenomenon)
[93]. One plausible mechanism of the warm-up is the
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enhanced activity of the muscle Na+/K+-ATPase induced by
exercise, which facilitates the clearance of extracellular K+
from transverse-tubules. A recent study inmyotonic patients,
however, failed to support this hypothesis [94], indicating
that the precise mechanism of warm-up is still unclear.
Also elusive are the rationales for several other clinical
manifestations of myotonia congenita. For example, the
recessive myotonia is usually more common in men than in
women, and for female patients of dominant myotonia, the
symptoms become worse during pregnancy [75]. It has been
suggested that the observed gender difference may arise from
the modulation of CLC-1 channel function by sex hormones
[95]. In addition, recessive but not dominant myotonia
is often associated with transient muscle weakness on the
initiation of movement [75, 96], a defect that is not predicted
by enhancedmuscle excitability. Obviously, a combination of
biophysical and cell biological studies in both in vitro and in
vivo models will be required for better understanding of the
clinical symptoms of myotonia congenita.
7. Concluding Remarks
ClC-1 channels play a crucial role in setting membrane
excitability in skeletal muscle. Despite of the numerous
documentations of the association between CLCN1 muta-
tions andmyotonia congenita, elucidation of themechanistic
link between genetic defects and pathogenesis is still at
the primitive stage. One major limitation to our better
understanding of this issue lies in the fact that protein
biosynthetic pathways as well as subcellular localization
patterns of CLC-1 channels in situ remain obscure. For
example, even though a significant Cl− conductance has been
identified in the transverse-tubule system, it remains incon-
clusive whether CLC-1 channels are actually expressed in the
transverse-tubule system. In the ADR (arrested development
of righting response) mouse that has been used as a model
for recessive myotonia [34, 69], immuonhistochemistry of
muscle cryosection located CLC-1 channels primarily in the
outer, sarcolemmal membrane, but not in the transverse-
tubule of skeletal muscle [97]. A similar conclusion on
sarcolemmal localization of CLC-1 channels was recently
reported in flexor digitorum brevis muscle fibers of wild-type
mice as well [98]. Biophysical and pharmacological studies in
a skinned rat skeletal muscle, however, demonstrated that the
transverse-tubule Cl− channel conductance was blocked by
9-AC, low intracellular pH, and protein kinase C activators
[18, 19, 96], all of which are known to affect the properties
of CLC-1 channels observed in the heterologous expression
system [32, 60, 61, 99]. As has been previously proposed
[19, 100], this apparent discrepancy may arise from the
possibility that the transverse-tubule system expresses certain
splice variants of CLC-1 channels that lack the epitope for
the antibody used in the immunofluorescence study, or that
the surrounding microenvironment in the transverse-tubule
system prevents the antibody from properly recognizing the
epitope in CLC-1 channels in situ. The field thus requires
more extensive studies on not only the gating mechanisms
but also the biosynthetic process and subcellular localization
of CLC-1 channels.
Myotonia congenita, therefore, is still in lack of a
standard, effective treatment. The field thus begs for further
research efforts in multiple directions. At the molecular
level, the mechanistic principles underlying the operation
of CLC-1 need to be further examined. At the cellular
level, the protein biosynthesis mechanisms of CLC-1 (protein
biogenesis, membrane trafficking, as well as subcellular local-
ization patterns in situ), although drawing much research
attention recently, remain obscure and need more in-
depth investigations. At the clinical level, many myotonia-
associated symptoms require better understanding of their
pathophysiological mechanisms. Through elucidations of the
physiological roles of CLC-1 and the pathophysiological
mechanisms of the CLC-1 channelopathy, the therapeutic
strategies for myotonia congenita will eventually be illumi-
nated.
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